X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (84) 84
oncology (71) 71
index medicus (69) 69
adult (60) 60
female (59) 59
middle aged (57) 57
male (56) 56
aged (50) 50
clinical neurology (49) 49
brain neoplasms - drug therapy (36) 36
glioblastoma (31) 31
chemotherapy (30) 30
medicine & public health (28) 28
treatment outcome (28) 28
cancer (23) 23
neurology (23) 23
glioblastoma - drug therapy (22) 22
disease-free survival (21) 21
neoplasm recurrence, local - drug therapy (21) 21
care and treatment (20) 20
angiogenesis (19) 19
glioma - drug therapy (19) 19
radiotherapy (19) 19
gliomas (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
article (16) 16
magnetic resonance imaging (16) 16
phase-ii trial (16) 16
bevacizumab (15) 15
dacarbazine - analogs & derivatives (15) 15
radiation (15) 15
retrospective studies (15) 15
aged, 80 and over (14) 14
brain tumors (14) 14
clinical trials (14) 14
glioblastoma multiforme (14) 14
malignant gliomas (14) 14
temozolomide (14) 14
clinical investigations (13) 13
malignant glioma (13) 13
tumors (13) 13
abstracts (12) 12
antineoplastic agents - therapeutic use (12) 12
brain neoplasms - pathology (12) 12
combined modality therapy (12) 12
glioma - pathology (12) 12
high-grade gliomas (12) 12
therapy (12) 12
analysis (11) 11
brain neoplasms - mortality (11) 11
neoplasm recurrence, local - pathology (11) 11
prognosis (11) 11
angiogenesis inhibitors - therapeutic use (10) 10
dacarbazine - administration & dosage (10) 10
endothelial growth-factor (10) 10
kaplan-meier estimate (10) 10
survival (10) 10
angiogenesis inhibitors (9) 9
antineoplastic agents - adverse effects (9) 9
bevacizumab plus irinotecan (9) 9
clinical trial (9) 9
follow-up studies (9) 9
health aspects (9) 9
medical colleges (9) 9
antimitotic agents (8) 8
antineoplastic agents (8) 8
brain (8) 8
brain neoplasms - genetics (8) 8
brain neoplasms - therapy (8) 8
glioblastoma - pathology (8) 8
glioma - mortality (8) 8
maximum tolerated dose (8) 8
meningeal neoplasms - drug therapy (8) 8
neoplasm recurrence, local - mortality (8) 8
surgery (8) 8
survival rate (8) 8
tyrosine kinase inhibitor (8) 8
vascular endothelial growth factor (8) 8
brain neoplasms - complications (7) 7
brain tumor (7) 7
glioblastoma-multiforme (7) 7
glioma (7) 7
high-grade glioma (7) 7
meningioma (7) 7
meningioma - drug therapy (7) 7
neoplasm staging (7) 7
patients (7) 7
recurrent glioblastoma (7) 7
survival analysis (7) 7
trial (7) 7
young adult (7) 7
adolescent (6) 6
antineoplastic agents - administration & dosage (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
brain neoplasms - radiotherapy (6) 6
brain-tumor consortium (6) 6
dacarbazine - adverse effects (6) 6
fatigue (6) 6
glioblastoma - radiotherapy (6) 6
hemorrhage (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1160 - 1160
Background: Neuro-oncology patients, like all cancer patients, are at a high risk for thromboembolic complications and frequently require treatment with... 
Journal Article
by Weller, Michael and Butowski, Nicholas and Tran, David D and Recht, Lawrence and Recht, Lawrence D and Lim, Michael and Hirte, Hal and Ashby, Lynn and Mechtler, Laszlo and Goldlust, Samuel and Goldlust, Samuel A and Iwamoto, Fabio and Drappatz, Jan and O'Rourke, James and O'Rourke, Donald M and Wong, Mark and Hamilton, Mark G and Hamilton, Mark and Finocchiaro, Gaetano and Perry, James and Wick, Wolfgang and Green, Jennifer and He, Yi and Turner, Christopher D and Yellin, Michael J and Keler, Tibor and Davis, Thomas A and Stupp, Roger and Sampson, John H and Campian, Jian and Becker, Kevin and Barnett, Gene and Nicholas, Garth and Desjardins, Annick and Benkers, Tara and Wagle, Naveed and Groves, Morris and Kesari, Santosh and Horvath, Zsolt and Merrell, Ryan and Curry, Richard and Schuster, David and Mrugala, Maciej and Jensen, Randy and Trusheim, John and Lesser, Glenn and Belanger, Karl and Sloan, Andrew and Purow, Benjamin and Fink, Karen and Raizer, Jeffrey and Schulder, Michael and Nair, Suresh and Peak, Scott and Brandes, Alba and Mohile, Nimish and Landolfi, Joseph and Olson, Jon and Jennens, Ross and DeSouza, Paul and Robinson, Bridget and Crittenden, Marka and Shih, Kent and Flowers, Alexandra and Ong, Shirley and Connelly, Jennifer and Hadjipanayis, Costas and Giglio, Pierre and Mott, Frank and Mathieu, David and Lessard, Nathalie and Sepulveda, Sanchez Juan and Lövey, József and Wheeler, Helen and Inglis, Po-Ling and Hardie, Claire and Bota, Daniela and Lesniak, Maciej and Portnow, Jana and Frankel, Bruce and Junck, Larry and Thompson, Reid and Berk, Lawrence and McGhie, John and Macdonald, David and Saran, Frank and Soffietti, Riccardo and Blumenthal, Deborah and André de, Sá Barreto Costa Marcos and Nowak, Anna and Singhal, Nimit and Hottinger, Andreas and Schmid, Andrea and Srkalovic, Gordan and Baskin, David and Fadul, Camilo and Nabors, Louis and LaRocca, Renato and Villano, John and Paleologos, Nina and ... and ACT IV Trial Investigators and ACT IV trial investigators
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1373 - 1385
Rindopepimut (also known as CDX-110), a vaccine targeting the deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet... 
GLIOMAS | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | GROWTH-FACTOR | RADIOTHERAPY | CANCER | PEPTIDE | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2008, Volume 7, Issue 12, pp. 1152 - 1160
Summary Background Despite optimum treatment with surgery, radiation therapy, and chemotherapy, most patients with malignant glioma have a poor prognosis.... 
Neurology | ANAPLASTIC ASTROCYTOMA | PHASE-II TRIAL | NEWLY-DIAGNOSED GLIOBLASTOMA | EUROPEAN ORGANIZATION | IN-VIVO | TUMOR ANGIOGENESIS | HIGH-GRADE GLIOMAS | METRONOMIC CHEMOTHERAPY | CLINICAL NEUROLOGY | ENDOTHELIAL GROWTH-FACTOR | RADIATION-THERAPY | Cerebral Arteries - immunology | Vascular Endothelial Growth Factor Receptor-2 - drug effects | Endothelial Cells - metabolism | Antibodies, Monoclonal - pharmacology | Humans | Brain Neoplasms - physiopathology | Angiogenesis Inhibitors - pharmacology | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Antibodies, Monoclonal - therapeutic use | Brain Neoplasms - blood supply | Vascular Endothelial Growth Factor Receptor-2 - immunology | Brain Neoplasms - drug therapy | Cerebral Arteries - drug effects | Endothelial Cells - immunology | Glioma - blood supply | Cerebral Arteries - metabolism | Neovascularization, Pathologic - drug therapy | Neovascularization, Pathologic - physiopathology | Antineoplastic Agents - pharmacology | Neovascularization, Pathologic - metabolism | Glioma - physiopathology | Glioma - drug therapy | Endothelial Cells - drug effects | Antimitotic agents | Care and treatment | Chemotherapy | Gliomas | Nuclear radiation | Antineoplastic agents | Health aspects | Vascular endothelial growth factor | Cancer | Corticoids | Fibroblast growth factor 2 | Hypertension | Brain tumors | Radiation | Blood vessels | Cytotoxicity | Angiopoietin receptors | Hemorrhage | Survival | Endothelial cells | Bevacizumab | Vascular endothelial growth factor receptors | Radiography | Angiogenesis | Side effects | Placenta | Glioma | Glioma cells | Monoclonal antibodies | Thromboembolism | Proteinuria
Journal Article
02/2018, Progress in Neurological Surgery, ISBN 9783318060584, Volume 31, 10
Oligodendrogliomas are therapy-responsive tumors, which have better prognosis compared to their astrocytic counterparts. The goal of treatment in such cases is... 
Chapter
Book Chapter
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2010, Volume 28, Issue 17, pp. 2817 - 2823
Journal Article
CONTINUUM: Lifelong Learning in Neurology, ISSN 1080-2371, 04/2012, Volume 18, Issue 2, Neuro-oncology, pp. 275 - 294
PURPOSE OF REVIEW:Patients with brain tumors require close attention to medical issues resulting from their disease or its therapy. Effective medical... 
Brain Edema - etiology | Humans | Middle Aged | Brain Edema - therapy | Thromboembolism - etiology | Brain Neoplasms - complications | Seizures - therapy | Thromboembolism - therapy | Cognition Disorders - etiology | Seizures - etiology | Adult | Female | Cognition Disorders - therapy
Journal Article
Journal Article
CONTINUUM: Lifelong Learning in Neurology, ISSN 1080-2371, 04/2012, Volume 18, Issue 2, pp. 275 - 294
PURPOSE OF REVIEW:Patients with brain tumors require close attention to medical issues resulting from their disease or its therapy. Effective medical... 
Journal Article
Journal Article